Hero

Management Team

Management Team

Senior Leadership
Pablo Legorreta

Pablo Legorreta

Founder & Chief Executive Officer

Mr. Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a rapidly growing life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry.

Mr. Legorreta serves on the Board of Directors of Epizyme (Nasdaq: EPZM) and on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute and Park Avenue Armory.

Mr. Legorreta is the founder and chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Since its foundation in 2010 AMSA has provided over 450 scholarships to Mexican and Latin American doctors and healthcare providers to study abroad. Mr. Legorreta has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.

Jim Reddoch, PhD

Jim Reddoch, PhD

Executive Vice President, Head of Research & Investments

Dr. Reddoch has led the team at Royalty Pharma that focuses on sourcing and analyzing new investment opportunities and partnerships for over 10 years. Prior to joining Royalty Pharma in 2008, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the board of Avillion, a London-based drug development company funded by Royalty Pharma and other investors, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. Dr. Reddoch has a BA from Furman University, a PhD in Biochemistry and Molecular Genetics from the University of Alabama, and was a postdoctoral fellow at Yale University.

Christopher Hite

Christopher Hite

Executive Vice President & Vice Chairman

Mr. Hite has over 24 years of experience advising pharmaceutical and biotechnology companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Mr. Hite was an investment banker at Citi where he was a Vice Chairman and the Global Head of Healthcare for nearly 12 years. Prior to joining Citi, Mr. Hite was the Global Head of Healthcare Investment Banking at Lehman Brothers.  Mr. Hite serves on the Board of Advisors of Faster Cures, a center of the Milken Institute.  Mr. Hite has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.

George Lloyd

George Lloyd

Executive Vice President, Investments & General Counsel

Mr. Lloyd focuses on transaction structuring and execution and also leads the legal and compliance function at Royalty Pharma. Mr. Lloyd joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. Mr. Lloyd was previously a partner in Goodwin Procter’s Private Equity Group and an associate in Davis, Polk & Wardwell’s New York and Paris offices. Mr. Lloyd has an AB from Princeton University and a JD from New York University Law School.

Terrance Coyne

Terrance Coyne

Chief Financial Officer

Mr. Coyne joined Royalty Pharma in 2010. Previously, Mr. Coyne was a biotechnology analyst at J.P. Morgan and Rodman & Renshaw, and began his career at Wyeth Pharmaceuticals. Mr. Coyne has a BS in business administration from La Salle University and an MBA from La Salle University.

“Our goal is to become the partner of choice for pharma and biotech companies, allowing them to focus their resources on strategic assets.”

Pablo Legorreta — Founder and Chief Executive Officer

Research and Investments
Molly Chiaramonte, PhD

Molly Chiaramonte, PhD

Senior Vice President, Research & Investments

Dr. Chiaramonte joined Royalty Pharma in 2008. Previously Dr. Chiaramonte was a biotechnology equity associate at Jefferies & Company. Dr. Chiaramonte has a BA from Providence College, an MA in mathematics from the University of Colorado, a PhD in chemistry from the University of Colorado, and was a postdoctoral fellow at the University of Colorado Health Sciences Center.

Marshall Urist, MD, PhD

Marshall Urist, MD, PhD

Senior Vice President, Research & Investments

Dr. Urist Joined Royalty Pharma in 2013. Previously, Dr. Urist was an executive director and the senior biotechnology analyst at Morgan Stanley. Dr. Urist has a BA, Phi Beta Kappa, from Johns Hopkins University, a PhD from Columbia University, and an MD from Columbia University.

Sara Klymkowsky

Sara Klymkowsky

Vice President, Research & Investments

Ms. Klymkowsky joined Royalty Pharma in 2012. Previously, Ms. Klymkowsky was an analyst in the Healthcare Investment Banking group at Goldman Sachs & Co. Ms. Klymkowsky has a BSBA and BA in molecular, cellular and developmental biology from the University of Colorado at Boulder.

Brienne Kugler

Brienne Kugler

Vice President, Research & Investments

Ms. Kugler joined Royalty Pharma in 2014. Previously, Ms. Kugler was a biotechnology equity research senior associate at Morgan Stanley. Ms. Kugler has a BS in materials science and engineering from Massachusetts Institute of Technology.

Jason Mehar

Jason Mehar

Vice President, Investments & Deputy General Counsel

Mr. Mehar joined Royalty Pharma in 2018. Previously, Mr. Mehar was an associate in the Mergers & Acquisitions groups of Gibson, Dunn & Crutcher and Davis Polk & Wardwell. Mr. Mehar has a BA in business from York University and a JD from Osgoode Hall Law School.

Volodymyr (Vlad) Nikolenko, PhD, MBA

Volodymyr (Vlad) Nikolenko, PhD, MBA

Vice President, Research & Investments

Dr. Nikolenko joined Royalty Pharma in 2017. Previously, Dr. Nikolenko was an equity research associate on the Evercore ISI biotech and pharma team. Mr. Nikolenko also previously was a senior financial analyst at Merck and a senior portfolio analyst at Columbia Technology Ventures. Dr. Nikolenko has a BS/MS from Moscow Institute of Physics and Technology, an MBA from Columbia University, and a PhD in neuroscience from Columbia University.

Gaurie Tilak, MD, MBA

Gaurie Tilak, MD, MBA

Senior Associate, Research & Investments

Dr. Tilak joined Royalty Pharma in 2019. Previously, Dr. Tilak was an associate in the healthcare practice at McKinsey and Company. Dr. Tilak has a BA from Brown University, an MD from Harvard University and an MBA from Harvard University.

Philip Liu

Philip Liu

Associate, Research & Investments

Mr. Liu joined Royalty Pharma in 2019. Previously, Mr. Liu was an associate in the investment banking and corporate finance group at Mizuho. Mr. Liu has a BS in Economics and a BA in Chemistry from Wharton and the University of Pennsylvania.

Max Yoon

Max Yoon

Associate, Research & Investments

Mr. Yoon joined Royalty Pharma in 2020. Previously, Mr. Yoon was a biotechnology equity research associate at Bank of America and an analyst in the Healthcare Investment Banking group at Citi. Mr. Yoon has a BA in Biological Sciences from Columbia University.

blank

Sam Glazer

Associate, Research & Investments

Mr. Glazer joined Royalty Pharma in 2020. Previously, Mr. Glazer was an analyst in the Biotech and Biopharma investment banking group at Piper Sandler. Mr. Glazer has a BA from Pomona College.

Investor Relations and Finance
George Grofik, CFA

George Grofik, CFA

Senior Vice President, Head of Investor Relations and Communications

Mr. Grofik joined Royalty Pharma in 2020. Previously, he served as VP, Head of Global Investor Relations at Sanofi. Prior to joining Sanofi, Mr. Grofik was the senior equity research analyst at Citi covering the U.S. large-cap pharmaceutical industry. He is a CFA®charterholder and holds a BS in accounting from Binghamton University.

Alexander von Perfall

Alexander von Perfall

Vice President, Investor Relations & Public Affairs

Mr. von Perfall joined Royalty Pharma in 2009. Previously, Mr. von Perfall was the co-founder and chief network officer of XTF, a start-up exchange traded fund ratings agency. Mr. von Perfall also previously worked for BMG Entertainment and Bertelsmann AG and the International Finance Corporation/World Bank Group. Mr. von Perfall serves on the boards of Lupus Therapeutics, a non-profit dedicated to accelerating the identification and development of new therapies to treat lupus and of the Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America. Mr. von Perfall has studied at the Hochschule St. Gallen in Switzerland, has a BA from the University of San Francisco, and an MBA from the Stern School of Business at New York University.

Kristin Stafford

Kristin Stafford

Chief Accounting Officer

Ms. Stafford joined Royalty Pharma in 2016. Previously, Ms. Stafford was a director at Ernst & Young LLP Capital Markets in London, specializing in US transactions involving European life sciences companies. Ms. Stafford also previously managed the external SEC reporting for iHeartMedia and was an auditor at Deloitte. Ms. Stafford has a BA, with honors, from Sonoma State University.

Jessica Veeramachaneni

Jessica Veeramachaneni

Vice President & Controller

Ms. Veeramachaneni joined Royalty Pharma in 2011. Previously, Ms. Veeramachaneni was an auditor at PricewaterhouseCoopers. Ms. Veeramachaneni has a BBA in accounting and is a Certified Public Accountant.

Sarah Cata

Sarah Cata

Vice President, Finance

Ms. Cata joined Royalty Pharma in 2014. Previously, Ms. Cata was an associate in the Healthcare Investment Banking group at J.P. Morgan. Ms. Cata has a BA in Spanish and a BS in finance and accounting from Miami University.

blank

Sam Landsberg

Vice President, Strategy and Financial Planning

Mr. Landsberg joined Royalty Pharma in 2020. Previously, Mr. Landsberg was a Vice President in the Healthcare Investment Banking group at Morgan Stanley, covering a variety of companies across the biopharmaceutical industry. Mr. Landsberg has a BS in business administration with a concentration in finance from Northeastern University.

Stephanie Ratner

Stephanie Ratner

Assistant Controller

Ms. Ratner joined Royalty Pharma in 2012. Previously, Ms. Ratner worked in forensic accounting. Ms. Ratner has a BS in accounting from Ramapo College of New Jersey and is a Certified Public Accountant.

CG

Christine Grueniger

Assistant Controller

Ms. Grueniger joined Royalty Pharma in 2020. Previously, Ms. Grueniger was a director at Perella Weinberg Partners, specializing in accounting for the Private Equity and Hedge Fund businesses. Prior to that, Ms. Grueniger was a senior management company accountant at Eton Park Capital Management, a multi-strategy hedge fund. Prior to that, Ms. Grueniger was an auditor at PricewaterhouseCoopers in the Banking and Capital Markets industry sector. Ms. Grueniger has a BS in Accounting from the University at Albany, New York and is a Certified Public Accountant.

Mina Fukuda

Mina Fukuda

Tax Director

Ms. Fukuda joined Royalty Pharma in 2015. Previously, Ms. Fukuda was a Tax Manager at Ernst & Young LLP in the Wealth and Asset Management division, working for an array of asset management clients, specializing in hedge fund and private equity taxation. Ms. Fukuda has a BS, summa cum laude, in accounting from the University of Maryland and is a Certified Public Accountant.